Replies to post #109348 on Biotech Values

[Shengli]

Do you know how many patients are enrolled in the phase 3 study ?
It looks like the phase 2 results were based on 50 patients. I hope they include more in the phase 3. But at first glance in that population the results are fantastic.Too bad for investors they are private

[DFRAI]

xray72
perhaps you should be checking ONCY - a public company who is in phase III and take a look at patent protection vis a vis Biovex - you might be surprised of what you find.

[jq1234]

So, in your opinion, this is not incremental change in cancer? Even for melanoma, this is nowhere near the most promising candidate, check Plexxikon (a private company) whose BRAF inhibitor PLX4032 with KNOWN mechanism of action showed 80% response rate. Even with 80% ORR it is still incremental improvement because it doesn't make metastatic melanoma a chronical disesase.

[rjc2827]

There’s an article out this morning on Biovex’s Oncovex, ONCY’s Reolysin, and other oncolytic viruses at:

http://biomedreports.com/2010112260394/oncolytic-viruses-are-they-the-future-of-cancer-therapy.html

rjc